Project Grant R01CA300792
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$710K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $674,996 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sanford Burnham Prebys Medical Discovery Institute. The goal of this 5-year project is to determine whether targeting the PSGL-1 immune checkpoint can promote the development and persistence of T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade therapy. The research aims to elucidate the role of PSGL-1 in driving T cell exhaustion and...
The National Cancer Institute (NCI) awarded a 5-year, $549,962 Project Grant (CFDA 93.396 - Cancer Biology Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant supports research to determine how antibodies and cellular ligands regulate the immunosuppressive function of the lymphocyte-activation gene 3 (LAG3) protein. The goal is to provide fundamental insight into LAG3 immunobiology and open new avenues for developing optimal...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $606,993 to Emory University to conduct research aimed at improving immune modulation for the treatment of smoldering multiple myeloma (SMM). The 5-year award, which begins on December 1, 2024, will evaluate properties of immune cells in SMM patients to determine their correlation with the risk of progression to clinical multiple myeloma. The research will also assess changes...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a 5-year, $532,970 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Icahn School of Medicine at Mount Sinai. The grant supports research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy.
Specifically, the research seeks to study the transcriptional programs and...
This $649,679 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research conducted by The Institute For Cancer Research to investigate a novel strategy for enhancing cancer immunotherapy responsiveness. The project aims to determine if targeting the RNA/DNA helicase DHX9 can induce "viral mimicry" in small cell lung cancer cells, triggering an antiviral immune response and improving the efficacy of immune checkpoint blockade...
The National Cancer Institute (NCI) awarded a $457,683 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope. The grant, with a period of performance from July 2, 2024 to June 30, 2026, will support research to develop a tumor-targeting bacterial platform that secretes chemokines and cytokines, referred to as "Bio-Beacons," to recruit and activate immune cells within solid tumors. The goal is to increase the...
This federal Project Grant award of $711,704 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports a study to investigate determinants of immune-related adverse events (IRAEs) in melanoma patients treated with combination immunotherapy. The primary objectives are to:
Assess whether levels of peripheral helper T (Tph) cells in pre-treatment blood can predict development of severe IRAEs in melanoma patients receiving combination immunotherapy.
Determine...
This $577,818 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop new therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers. The award supports research at Mayo Clinic to investigate the role of the immune checkpoint molecule B7-H3 in mediating tumor immune evasion, with the goal of overcoming resistance to radiotherapy. The...
This federal Project Grant award from the National Cancer Institute (NCI), as part of the Cancer Treatment Research program (CFDA 93.395), provides funding of $576,659 to Emory University to conduct research on tumor and host immune signatures associated with racial disparities in outcomes for patients with high-risk neuroblastoma receiving GD2 immunotherapy. The key objectives are to: 1) Investigate tumor immune microenvironment factors influencing event-free and overall survival, 2) Define...
This federal Project Grant award, valued at $154,568 and awarded by the National Cancer Institute (NCI), will support research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The research aims to enhance understanding of how ILC3s modulate adaptive immune responses, which could inform novel combination treatment strategies to improve the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced...